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Abstract
Background: Inflammation is associated with increased bone resorption; the role of inflammation in postprandial
bone turnover has not been explored. Consumption of milk fat globule membrane (MFGM) reduces inflammation
in animal models. This study aimed to measure postprandial changes in bone turnover after intake of high saturated
fat test meals, with- and without the anti-inflammatory ingredient MFGM.
Methods: Subjects (n = 36 adults) were obese (BMI 30–39.9 kg/m2) or overweight (BMI 25–29.9 kg/m2) with two traits
of Metabolic Syndrome. Subjects consumed a different test meal on four occasions at random; blood draws were
taken at baseline and 1, 3, and 6 h postprandial. Test meals included whipping cream (WC), WC +MFGM, palm oil (PO)
and PO +MFGM. Biomarkers of bone turnover and inflammation were analyzed from all four time points.
Results: Test meal (treatment) by time interactions were significant for bone resorption marker C-telopeptide of type 1
collagen (CTX) (p < 0.0001) and inflammatory marker interleukin 10 (IL-10) (p = 0.012). Significant differences in overall
postprandial response among test meals were found for CTX and soluble intercellular adhesion molecule (sICAM), with
the greatest overall postprandial suppression of CTX occurring in meals containing MFGM. However, test meal by
MFGM interactions were non- significant for bone and inflammatory markers. Correlations between CTX and
inflammatory markers were non-significant.
Conclusion: This exploratory analysis advances the study of postprandial suppression of bone turnover by
demonstrating differing effects of high SFA meals that contained MFGM; however MFGM alone did not directly
moderate the difference in postprandial CTX response among test meals in this analysis. These observations may
be useful for identifying foods and ingredients which maximize the suppression of bone resorption, and for
generating hypotheses to test in future studies examining the role of inflammation in postprandial bone turnover.
Trial registration: Clinicaltrials.gov NCT01811329. Registered 11 March 2013.
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Background
Biomarkers of bone resorption have been observed to
fluctuate over the course of a day, with a peak occurring
at night and a nadir seen in the day, particularly in the
late afternoon. This pattern appears exaggerated with
food intake [1–3]. Consumption of glucose suppresses
bone resorption marker C- telopeptide of type I collagen
(CTX) by 45–50% approximately 120 min after intake in
healthy subjects [4, 5]. Mixed meals induce a similar but
delayed reduction in CTX approximately 180 min after
eating [5, 6]. In contrast to bone resorption, bone forma-
tion markers such as N-terminal serum type 1 procolla-
gen (P1NP) change less drastically in the postprandial
state [1, 4]. Explanations for the postprandial suppression
of bone turnover have focused primarily on insulin and
incretin hormones, but additional factors such as inflam-
matory mediators may contribute to the observed reduc-
tion in circulating CTX in the postprandial period [5].
In the Post-Prandial Inflammation (PPI) study, our
group showed that the addition of a dairy fraction rich
in milk fat globule membrane (MFGM) reduced post-
prandial concentrations of cholesterol, inflammatory
markers and insulin in overweight and obese subjects
who consumed test meals high in saturated fatty acids
(SFA) [7]. MFGM was selected as a key ingredient due
to its reported anti-inflammatory properties [8]. Com-
posed of sphingolipids and glycerophospholipids, as well
as proteins, MFGM covers the apical surface of lipid
droplets produced by mammary glands [8, 9]. Whole
buttermilk that was created during butter churning in
decades past was a naturally rich source of MFGM, but
today MFGM can be isolated, purified and added to
other foods [9]. MFGM has been shown to reduce in-
flammation [10], improve endurance capacity and lipid
metabolism [11] in animals, as well as reduce frailty in
elderly women [12]. To date, effects of MFGM on bone
outcomes have not been investigated in clinical studies.
The PPI study provided the opportunity to conduct ex-
ploratory analyses of potential associations between
postprandial bone turnover and postprandial inflamma-
tion using MFGM.
The aims of the present project were to examine post-
prandial changes in bone turnover after intake of high
SFA challenge meals (with and without MFGM), and to
investigate the relationships between the responses of in-
flammatory markers and bone turnover markers to the
test meals. Since inflammation has been associated with
increased bone resorption [13], and we previously showed
that the addition of MFGM to a high SFA challenge meal
reduces inflammatory markers [7], we hypothesized that
due to anti-inflammatory effects of MFGM, high SFA
challenge meals containing MFGM would attenuate post-
prandial bone turnover markers to a greater extent than
high SFA challenge meals without MFGM.
Methods
Participants
Details of the PPI study have been previously published
[7]. Briefly, subjects were recruited from the Davis and
greater Sacramento areas of California and included 36
adults (19 women and 17 men). Inclusion criteria were
18–65 years of age and a body mass index (BMI) classi-
fied as obese (BMI 30–39.9 kg/m2) or overweight (BMI
25–29.9 kg/m2) plus two traits of Metabolic Syndrome
(MetS). Per the American Heart Association definition,
MetS traits include blood pressure ≥ 130/85 mmHg, fast-
ing plasma triglyceride ≥ 150 mg/dl, fasting plasma high
density lipoprotein (HDL) cholesterol < 40 mg/dl for
men and < 50 mg/dl for women, waist circumference >
40 inches for men and 35 inches for women, and fasting
glucose ≥ 100 mg/dl [14]. Exclusion criteria included
gastrointestinal disorders, type 2 diabetes, immune-
related disorders, cancer, self-reported eating disorder,
use of anti-inflammatory pain medication, use of over
the counter anti-obesity agents or corticosteroids in the
last 12 weeks, initiation of statin therapy in the last
12 weeks, initiation of fish, krill, flax, borage or primrose
seed oils within the last 12 weeks, use of dietary supple-
ments with concentrated soy isoflavones, resveratrol or
other polyphenols, initiation, change or cessation of hor-
monal birth control in the last 6 months, known allergy
or intolerance to study food, adherence to a vegetarian
diet, consumption of >1% of energy from trans-fats, > 1
serving of fish per week, > 14 grams of fiber per
1000 kcal/day, <16:1 total omega-6:omega 3 fatty acid
ratio, >10% weight loss or gain in the past 6 months,
poor vein assessment determined by phlebotomist, use
of tobacco products, initiation of a new exercise pro-
gram in the last month, and pregnancy, lactation, or
plans to become pregnant in the next 6 months. Fulfill-
ment of enrollment criteria was determined through
questionnaires, analysis of a fasting blood sample for
blood lipids and glucose, and anthropometric measure-
ments (height, weight, waist circumference) that were
taken during the subjects’ screening visits. The study
protocol was approved by the Institutional Review Board
of the University of California at Davis, and all proce-
dures performed in the study were in accordance with
the ethical standards of the 1964 Helsinki Declaration
and its later amendments or comparable ethical stan-
dards. Informed consent was obtained from all individ-
ual participants included in the study. The study was
registered at clinicaltrials.gov under NCT01811329.
Study design
Phone screenings were used to determine subject eligibil-
ity, after which the individual reported to the Western Hu-
man Nutrition Research Center (WHNRC) to complete
consent forms. Subjects were randomized to one of four
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treatment sequences in a repeated measures Latin Square
design (Fig. 1). The advantage of this design for a repeated
measures experiment is that it ensures a balanced fraction
of all treatment combinations when subjects are limited
and the sequence effect of treatment can be considered to
be negligible. Investigators were blind to treatment order.
A washout period of 1–2 weeks was observed between
treatments to prevent carry-over effects across treatments.
A random allocation sequence generator (randomization.-
com; seed#4234) was used to assign treatment order.
Subjects were instructed to abstain from alcohol,
NSAIDs, and other anti-inflammatory supplements 72 h
before each test day and from vigorous exercise and con-
suming seafood 24 h before each test day. Additionally,
subjects recorded their diets 24 h before each test day.
Nutrition Data System for Research (NDSR; University
of Minnesota) was used to assess the 1-day diet record
for compliance with the pre-study instructions.
The study took place at the WHNRC in Davis, CA.
Subjects fasted for 10–12 h prior to each study day. Sub-
jects completed a modified gastrointestinal questionnaire
[15] and provided a fasting blood draw at the beginning
of each study day. Blood pressure, heart rate, weight and
waist circumference measurements were also recorded.
Subjects then consumed the “breakfast” test meal within
20 min, and postprandial blood draws were taken at 1, 3,
and 6 h (Fig. 1). Subjects were not allowed to consume
any additional food throughout the study day but could
drink bottled water ad libitum. Subjects were also
instructed to minimize their physical activity during the
remaining time of the test day by either staying at the
test center for the entire 7-hour period or traveling by
car if they chose to leave between blood draws. If sub-
jects left and returned to the center, they were instructed
to arrive 15 min prior to their scheduled blood draw to
allow for a 10 min rest period before the venipuncture.
Test meals
Meals consisted of a smoothie, as well as a bagel with
strawberry preserves. Smoothies were made from
whipping cream (WC) or palm oil (PO); milk fat globule
membrane (MFGM) was added to one WC smoothie
(WC +MFGM) and one PO smoothie (PO +MFGM). In
this study, MFGM was sourced from the complex milk
lipid fraction powder BPC50 (Fonterra Co-operative
Group Ltd., Auckland, New Zealand) [16]. The compos-
ition of BPC50 includes the following (%wt/wt): 52%
protein (13.2% membrane-derived protein), 6.6% lactose,
and 36.2% total fat (22.5% triglycerides and 13.7% phos-
pholipids, 0.63% gangliosides (GD3), and 5.2% ash) [17–
19]. BPC50 contains the following MFGM-derived pro-
teins in greatest abundance: fatty acid binding protein,
butyrophilin, lactadherin, adipophilin, xanthine oxidase,
and mucin [18]. Because the WC and PO smoothies did
not contain BPC50, whey protein isolate was added to
match the protein content. The nutrient composition of
the test meals is shown in Additional file 1. Test meal
ingredients are listed in the Additional file 2.
Each test meal was customized to provide 40% of each
subject’s total energy intake (EI), as determined by the
National Academy of Sciences equation from the Insti-
tute of Medicine Dietary Reference Intake. This equation
accounted for gender, age, weight, height and physical
activity [20]. The Baecke Physical Activity questionnaire
was used to determine habitual physical activity [21].
The composition of each test meal was approximately
55% fat (49–87 grams per individual EI), 30% carbohy-
drate (61–107 grams per individual EI, and 15% protein
(31–55 grams per individual EI). The NDSR was used to
estimate the nutrient composition of each test meal.
MFGM replaced 31% of the fat in each meal (34% of
total kcal, 53.2–93.1) grams depending on individual EI).
Per study protocol, subjects consumed each meal in its
entirety, rinsed the beverage cup with bottled water and
drank the rinse water.
Blood analyses
A trained phlebotomist at the WHNRC collected blood
by venipuncture at each time point. Whole blood was
centrifuged in a tabletop ultracentrifuge for 15 min at
Fig. 1 Study design. Test meals: palm oil (PO), palm oil plus milk fat globule membrane (PO +MFGM), whipping cream (WC), whipping cream
plus milk fat globule membrane (WC +MFGM). Venipuncture timeline: 0 = baseline, B = breakfast test meal, 1 = 1 hour postprandial, 3 = 3 hours
postprandial, 6 = 6 hours postprandial. N = 36
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4 °C at 1300 × g within 30 min of collection. Plasma was
then separated into 1.5 mL aliquots and immediately
frozen at −70 °C until analysis. Serum was allowed to
clot on ice for 30 min, centrifuged for 15 min at 4 °C at
1300 × g and transferred into 1.5 mL aliquots and frozen
at −70 °C until analysis.
Bone biomarkers
C-telopeptide of type 1 collagen (CTX) was measured by
enzyme linked immune-sorbent assay (ELISA) (Immu-
nodiagnostic Systems, Inc., Gaithersburg, MD, USA).
Type 1 C-terminal collagen propeptide (C1CP) was also
measured by ELISA (Quidel Corporation, San Diego,
CA, USA).
Inflammatory markers
Inflammatory biomarker analyses were conducted at all
four time points. An electro-chemiluminescence detec-
tion system using multi-array technology (SECTOR
Imager 2400, Meso Scale Discovery) was used to analyze
interleukin-6 (IL-6), interleukin-18 (IL-18), interleukin-1
(IL-1), tumor necrosis factor alpha (TNFα), C-reactive
protein (CRP) and soluble intercellular adhesion mol-
ecule (sICAM) per manufacturer’s instructions. Plasma
was used to measure IL-18; serum was used to measure
all other inflammatory markers. In brief, 25–50 μL of
serum or plasma was added to pre-coated plates con-
taining capture antibodies. After incubation, plates were
washed, and a labeled detection antibody was added.
The bound detection antibodies emit light upon electro-
chemical stimulation, and a plate reader was used to
quantify each protein of interest.
Metabolic parameters
Assessment of plasma glucose, triglycerides, HDL-
cholesterol and insulin was completed at the clinical la-
boratory at the University of California Medical Center
(Sacramento, CA) using standard clinical techniques.
Clinical characteristics
Anthropometric data were collected at the time of
screening. Measurements included height (Ayrton Stadi-
ometer Model S100; Ayrton Corporation), body weight
(6002 Wheelchair Scale; Scale-tronix), waist circumfer-
ence measured in the standing position midway between
the lower rib margin and ileac crest (QM2000 Measure
Mate; QuickMedical), blood pressure and resting heart
rate (Carescape V100 with Critikon Dura-cuff for either
adults or large adults; GE Medical Instruments). BMI
was calculated as kg/m2. Bone density was also mea-
sured by dual energy X-ray absorptiometry (DXA, Lunar
Prodigy instrument; GE Medical Instruments).
Statistical analyses
Sample size to detect a minimum significant difference
between treatment groups was determined for the ori-
ginal PPI study, and power calculations were based on
previously published plasma inflammatory marker data
[22] and preliminary oxylipin studies in our lab. We de-
fined the minimal detectable difference as the difference
between the maximum and minimum responses; for ex-
ample, the magnitude of this difference was 34.1 for
prostaglandin E2 (PGE2). With a significance level set at
a two-sided alpha of 0.05 and power held at 80%, we cal-
culated that a sample size of 36 subjects was needed for
this four-way crossover trial.
Descriptive statistics (mean ± standard deviation) were
calculated for subjects’ baseline characteristics (Tables 1
and 2). Data were tested for normality with the Shapiro-
Wilk test and transformed as appropriate. A repeated
measures mixed model analysis (including the random
effects of subject and subject by treatment) was used to
test the effects of time, treatment (test meal) and time
by treatment interaction for the bone marker variables
(C1CP, CTX) and inflammatory variables (IL-6, IL-18,
TNF-α, CRP, IL-10, sICAM) (Table 3).
Additionally, a summary measure (incremental area
under the curve, iAUC) using the trapezoid method, was
used for comparison of overall postprandial responses
among test meals [23]. For bone markers and inflamma-
tory variables, the mean incremental area under the
Table 1 Subject baseline characteristicsa
Mean ± SD MetS criteriab
Age (years) 42.9 ± 14.0 —
Weight (kg) 92.9 ± 12.2 —
Height (m) 1.7 ± 0.1 —
BMI, (kg/m2) 31.7 ± 2.6 —
Total Body Fat (%) 36.7 ± 7.8 —
Total Body Fat, Male (%) 30.9 ± 6.2 —
Total Body Fat, Female (%) 41.9 ± 4.9 —
Waist circumference (inches) 39.3 ± 3.2 —
Waist circumference, Male (inches)c 41.1 ± 3.1 >40
Waist circumference, Female (inches)c 37.9 ± 2.2 >35
Systolic blood pressure (mmHg) 123.9 ± 13.6 ≥130
Diastolic blood pressure (mmHg) 75.0 ± 10.3 ≥85
HDL cholesterol (mg/dl) 48.3 ± 14.1 —
HDL cholesterol, Male (mg/dl)c 43.2 ± 11.7 <40
HDL cholesterol, Female (mg/dl)c 52.9 ± 14.7 <50
Fasting glucose (mg/dl) 91.0 ± 7.4 ≥100
Fasting triglycerides (mg/dl) 122.5 ± 57.8 ≥150
aMeasurements taken at screening visit (n = 36). BMI body mass index, HDL
high-density lipoprotein
bMetS as defined by the American Heart Association [14]. MetS metabolic syndrome
cMale n = 17, Female n = 19
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transformed curve (iAUtC) of each test meal was com-
pared by repeated measures analysis of covariance,
including fixed effects of group and subject, and trans-
formed hour 0 as a covariate (Table 4).
To examine whether postprandial changes in inflam-
matory variables may have mediated postprandial
changes in the bone markers, within-subject correlations
between iAUtC of inflammatory variables and iAUtC of
bone markers were examined, controlling for hour 0
values (Table 5). Correlation coefficients were calculated
as partial Pearson correlations; mixed model regression
(with a random effect of subject) was used to calculate
p-values for each correlation in order to account for the
fact that the four measurements were not independent
of each other. Additionally, we calculated correlations
between CTX and selected metabolic variables (glucose,
HDL cholesterol, triglycerides and insulin) at each time
point (Additional file 3).
GraphPad Prism 6.0c (GraphPad Software, Inc., La
Jolla, CA) and SAS for Windows release 9.4 (SAS Insti-
tute, Cary, NC) were used for statistical analyses.
Results
Out of 207 potential subjects who were screened, 38
subjects were enrolled. Two subjects were disqualified
due to initiation of medication that could confound the
results and to scheduling difficulties. The final subject
population included 17 males and 19 females. Details of
subject enrollment, CONSORT Diagram and follow up
have been previously published [7]. All subjects (n = 36)
consumed all four test meals. One subject did not
complete the postprandial blood draws after the PO +
MFGM test meal due to difficulties with the
venipuncture. The missing data for the 1, 3 and 6 h time
points for this subject were accounted for in the statis-
tical analyses per SAS protocol. For the correlations, the
missing points were omitted from the analysis. For the
various mixed model analyses, the non-missing points
were included, and the missing points were excluded,
but the nature of the model is that it implicitly imputes
the missing values when estimating differences between
the means for the treatments or the time points.
Baseline characteristics of the subjects were assessed
at the consent visit and are shown in Table 1. Subjects
were predominately Caucasian (67%) or Hispanic (28%).
On average, subjects were obese and met MetS criteria
for waist circumference and HDL cholesterol. Mean
bone mineral content (BMC), bone mineral density
(BMD), and T scores of male and female subjects are
shown in Table 2. Bone measurements were taken once
during the study to establish the baseline bone health of
each subject. Mean T-scores for lumbar spine, total right
hip and total left hip were within the normal range for
male and female subjects.
Effects of treatment and time were significant for CTX
(p ≤ 0.0001), and significant effects of time (p < 0.0001)
were also observed for IL-6, IL-18, TNF-α, CRP and
sICAM (Table 3). There were significant treatment by
time interactions for CTX (p < 0.0001) and IL-10 (p =
0.012) (Table 3).
Postprandial CTX concentrations (mean ± SD) after
each test meal are presented in Fig. 2. Differences in
CTX response to the test meals were most apparent at
6 h postprandial; CTX concentrations remained lower at
this time point after consumption of WC +MFGM and
PO +MFGM test meals compared to WC and PO test
meals.
Significant differences in overall postprandial response
(iAUtC) among the test meals were found for CTX and
sICAM. Test meal by MFGM interactions were not sig-
nificant for any of the bone or inflammatory markers
(Table 4).
The correlation between the iAUtCs of C1CP and IL-6
was statistically significant (r = −0.20; p = 0.045), but
other correlations between bone markers and inflamma-
tory variables were non-significant (Table 5).
Discussion
This exploratory study is the first to examine the poten-
tial role of inflammation in postprandial bone turnover.
In line with previous reports of postprandial bone turn-
over [5, 6] and as we observed with some of the inflam-
matory markers [7], bone resorption marker CTX
significantly changed over time in the postprandial state.
Interestingly, we observed that meals containing MFGM
induced the greatest overall suppression of CTX, par-
ticularly at 6 h postprandial; however, test meal by
MFGM interactions were non-significant. Furthermore,
although a weak correlation was found between bone
formation marker C1CP and IL-6, correlations between
CTX and the inflammatory variables were not statisti-
cally significant. Taken together, these data suggest that
suppression of postprandial inflammation may have a
Table 2 Bone mineral measurementsa of subjects at baseline
(Mean ± SD)
BMC (g) BMD (g/cm2) T-score
Males (n = 17)
Lumbar Spine L1-L4 81.00 ± 13.3 1.13 ± 0.1 0.39 ± 1.1
Total Right Hip 48.83 ± 8.7 1.12 ± 0.1 0.58 ± 0.9
Total Left Hip 46.81 ± 14.0 1.12 ± 0.1 0.61 ± 0.9
Females (n = 19)
Lumbar Spine L1-L4 62.17 ± 8.6 1.05 ± 0.1 0.05 ± 1.0
Total Right Hip 31.49 ± 8.2 0.98 ± 0.1 0.33 ± 1.0
Total Left Hip 34.29 ± 5.0 1.00 ± 0.1 0.43 ± 1.0
aMeasurements taken by dual energy X-ray absorptiometry, BMC bone mineral
content, BMD bone mineral density, T score = comparison to young adult average
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Table 3 Concentrations of postprandial bone biomarkers and inflammatory markers (Mean ± SD)
Postprandial time point
0 hour 1 hour 3 hour 6 hour Treatment effect
p-value
Time effect
p-value
Time x treatment
interaction p-value
C1CP (ng/ml) 0.093 0.084 0.195
PO +MFGM 134.4 ± 140.6 131.1 ± 134.1 128.1 ± 119.9 131.3 ± 127.7
PO 122.0 ± 133.7 127.1 ± 138.7 117.5 ± 124.2 127.9 ± 152.0
WC +MFGM 130.0 ± 135.2 126.2 ± 137.0 130.1 ± 146.5 129.3 ± 125.9
WC 153.1 ± 269.9 137.8 ± 201.7 123.6 ± 133.8 129.2 ± 146.3
CTX (ng/ml) 0.0001 <0.0001 <.0001
PO +MFGM 0.57 ± 0.27 0.33 ± 0.14 0.24 ± 0.12 0.32 ± 0.16
PO 0.53 ± 0.22 0.31 ± 0.13 0.24 ± 0.12 0.44 ± 0.22
WC +MFGM 0.56 ± 0.27 0.33 ± 0.16 0.22 ± 0.11 0.26 ± 0.14
WC 0.55 ± 0.26 0.31 ± 0.11 0.20 ± 0.09 0.38 ± 0.20
IL-6 (pg/ml) 0.449 <0.0001 0.975
PO +MFGM 0.72 ± 1.37 0.59 ± 1.26 0.54 ± 0.98 0.76 ± 1.40
PO 0.74 ± 1.08 0.59 ± 0.87 0.61 ± 1.09 0.76 ± 1.16
WC +MFGM 0.78 ± 1.43 0.63 ± 1.27 0.60 ± 1.20 0.86 ± 1.48
WC 0.70 ± 1.10 0.63 ± 1.18 0.60 ± 1.13 0.87 ± 1.51
IL-18 (pg/ml) 0.671 <0.0001 0.245
PO +MFGM 11.11 ± 3.33 11.32 ± 3.32 10.72 ± 2.74 10.80 ± 3.39
PO 11.24 ± 3.10 10.51 ± 3.34 9.629 ± 3.15 10.96 ± 2.95
WC +MFGM 11.79 ± 3.64 10.63 ± 4.11 10.40 ± 3.67 10.81 ± 3.17
WC 11.05 ± 3.44 10.98 ± 3.03 10.09 ± 2.69 10.18 ± 3.06
TNFα (pg/ml) 0.679 <0.0001 0.303
PO +MFGM 2.34 ± 0.67 2.36 ± 0.66 2.27 ± 0.62 2.22 ± 0.68
PO 2.49 ± 0.71 2.36 ± 0.56 2.29 ± 0.63 2.36 ± 0.64
WC +MFGM 2.54 ± 0.83 2.36 ± 0.81 2.32 ± 0.81 2.32 ± 0.73
WC 2.44 ± 0.70 2.38 ± 0.67 2.27 ± 0.57 2.32 ± 0.63
CRP (mg/l) 0.207 <0.0001 0.608
PO +MFGM 1.49 ± 0.85 1.51 ± 0.86 1.46 ± 0.85 1.52 ± 0.87
PO 1.55 ± 0.86 1.65 ± 0.87 1.58 ± 0.88 1.62 ± 0.87
WC +MFGM 1.49 ± 0.85 1.56 ± 0.90 1.51 ± 0.87 1.56 ± 0.88
WC 1.49 ± 0.83 1.58 ± 0.90 1.50 ± 0.84 1.53 ± 0.86
IL-10 (pg/ml) 0.278 0.206 0.012
PO +MFGM 0.49 ± 1.17 0.52 ± 1.19 0.52 ± 1.12 0.57 ± 1.14
PO 0.56 ± 1.37 0.54 ± 1.35 0.54 ± 1.22 0.51 ± 1.32
WC +MFGM 0.52 ± 1.08 0.57 ± 1.09 0.57 ± 1.04 0.58 ± 1.17
WC 0.52 ± 1.13 0.58 ± 1.15 0.58 ± 1.21 0.55 ± 1.28
sICAM (mg/l) 0.168 <0.0001 0.114
PO +MFGM 0.96 ± 0.51 0.97 ± 0.51 0.95 ± 0.51 0.97 ± 0.53
PO 0.97 ± 0.51 1.058 ± 0.54 1.00 ± 0.51 1.044 ± 0.54
WC +MFGM 0.93 ± 0.50 0.99 ± 0.53 0.97 ± 0.54 0.97 ± 0.51
WC 0.92 ± 0.48 1.00 ± 0.52 0.96 ± 0.49 0.96 ± 0.49
Actual (untransformed) values are presented here; analysis was done on the transformed data. N = 36
Test meals: palm oil plus milk fat globule membrane (PO +MFGM), palm oil (PO), whipping cream plus milk fat globule membrane (WC +MFGM),
whipping cream (WC)
Bone variables: type 1 C-terminal collagen propeptide (C1CP), C-telopeptide of type 1 collagen (CTX)
Inflammatory variables: interleukin-6 (IL-6), interleukin-18 (IL-18), tumor necrosis factor alpha (TNFα), C-reactive protein (CRP), interleukin-10 (IL10),
soluble intercellular adhesion molecule (sICAM)
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minimal role in the suppression of postprandial bone
turnover and that MFGM did not directly moderate the
difference in postprandial CTX response among test
meals. However, further studies are warranted to con-
firm these observations.
The mechanisms of postprandial suppression of bone
turnover are incompletely understood. During fasting
(and especially during overnight fasts) the body must
mobilize nutrients from the bone for calcium homeosta-
sis and cell growth processes, and therefore bone resorp-
tion increases. It has been hypothesized that since
organic compounds and nutrients are readily available to
the skeleton after eating, bone resorption is unnecessary
in the postprandial state [1]. Differing effects of nutri-
ents and foods on postprandial bone resorption have
been reported. A small study of healthy adults compared
carbohydrate, fat and protein and found that all macro-
nutrients suppressed postprandial CTX compared to
baseline levels; however the postprandial CTX response
to fat ingestion was more blunted [24]. In contrast, other
researchers have observed a trend for greater CTX sup-
pression with lower protein, higher fat foods [2]. The
present study demonstrates differences in postprandial
CTX suppression among high SFA meals containing an
ingredient with anti-inflammatory properties (MFGM).
Previous work has revealed that bile acids [25], insulin
[5] and incretin hormones such as glucose dependent
insulinotropic peptide (GIP) may contribute to postpran-
dial suppression of bone resorption [24, 26]; however,
the PPI protocol did not include any measurements of
bile acids or incretin hormones, or insulin at 6 h post-
prandial. Per the PPI protocol, insulin was measured at
0, 1 and 3 h postprandial, and we examined correlations
between CTX and other selected metabolic variables
Table 4 Postprandial response (iAUtC1 ± SD) of bone biomarkers and inflammatory markers by test meal
Test meals Test Meal x MFGM interaction
p-valuePO +MFGM PO WC +MFGM WC
C1CP −0.18 ± 0.9 0.07 ± 1.2 0.01 ± 0.9 −0.28 ± 0.8 0.859
CTX −1.52 ± 1.0b −1.16 ± 0.9a −1.67 ± 0.9c −1.49 ± 0.9bc 0.332
IL-6 −0.70 ± 1.5 −0.78 ± 1.4 −0.84 ± 1.5 −0.47 ± 1.0 0.846
IL-18 −1.93 ± 10.6 −5.58 ± 11.4 −6.68 ± 11.0 −3.81 ± 11.5 0.106
TNF-α −0.12 ± 0.7 −0.36 ± 0.6 −0.49 ± 0.7 −0.26 ± 0.7 0.102
CRP 0.04 ± 0.3 0.12 ± 0.2 0.10 ± 0.2 0.08 ± 0.2 0.119
IL-10 0.71 ± 1.8 −0.25 ± 1.8 0.37 ± 1.7 0.19 ± 1.7 0.567
sICAM 0.13 ± 0.5b 0.37 ± 0.4a 0.28 ± 0.4ab 0.32 ± 0.5ab 0.080
1Mean incremental area under transformed curve
Significant differences in iAUtC of bone biomarkers and inflammatory markers among test meals are indicated by superscript letters
N = 36
Test meals: palm oil plus milk fat globule membrane (PO +MFGM), palm oil (PO), whipping cream plus milk fat globule membrane (WC +MFGM), whipping cream (WC)
Bone variables: type 1 C-terminal collagen propeptide (C1CP), C-telopeptide of type 1 collagen (CTX)
Inflammatory variables: interleukin-6 (IL-6), interleukin-18 (IL-18), tumor necrosis factor alpha (TNFα), C-reactive protein (CRP), interleukin-10 (IL-10), soluble intercellular
adhesion molecule (sICAM)
Table 5 Within-subject correlations of bone biomarkers and
inflammatory markersa
Inflammatory
variable
C1CP correlation
coefficient
p-value CTX correlation
coefficient
p-value
IL-6 −0.20 0.045 −0.08 0.421
IL-18 −0.09 0.338 −0.12 0.202
TNF-α −0.15 0.118 0.05 0.613
CRP 0.14 0.159 0.08 0.445
IL-10 0.02 0.877 −0.10 0.307
sICAM 0.03 0.748 0.01 0.935
aCorrelations calculated for incremental area under the transformed curve,
controlling for hour 0 values of the two variables. Correlation coefficients were
calculated as partial Pearson correlations; mixed model regression (with a
random effect of subject) was used to calculate p-values for each correlation
in order to account for the fact that the four measurements were not
independent of each other. N = 36
Bone variables: type 1 C-terminal collagen propeptide (C1CP), C-telopeptide of
type 1 collagen (CTX)
Inflammatory variables: interleukin-6 (IL-6), interleukin-18 (IL-18), tumor necrosis
factor alpha (TNFα), C-reactive protein (CRP), interleukin-10 (IL-10), soluble
intercellular adhesion molecule (sICAM)
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Fig. 2 Postprandial CTX concentrations over time after consumption
of four high SFA test meals. Test meals: palm oil (PO), palm oil plus
milk fat globule membrane (PO +MFGM), whipping cream (WC),
whipping cream plus milk fat globule membrane (WC +MFGM). N = 36
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(glucose, HDL cholesterol, triglycerides and insulin) at
each time point separately. Other studies have suggested
associations between bone turnover and cholesterol [27,
28], so the positive correlations that we observed be-
tween CTX and HDL cholesterol and negative correla-
tions between CTX and triglycerides warrant further
study (Additional file 3). We found no significant corre-
lations between CTX and insulin at any of the three
time points (Additional file 3).
We may have been unable to detect significant test
meal by MFGM interactions due to the fact that the
test meals were not matched for individual SFA’s
(Additional file 1). Additionally, the PPI nutrient ana-
lysis did not include micronutrients such as calcium,
which may influence bone turnover in the postprandial
state [29]. Moreover, the study was designed to com-
pare effects of the test meals against each other, so
there was no control group with which to make com-
parisons. Furthermore, the sample size was calculated
for the original PPI study based on plasma inflamma-
tory marker and oxylipin data rather than bone turn-
over markers. Our sample size (n = 36) is comparable to
that of other crossover studies using bone turnover
markers [5, 30]; it is unlikely that the sample size was a
major limitation in these exploratory analyses but this
remains a possibility. Lastly, our protocol allowed sub-
jects to leave the WHNRC if they traveled by car and
returned 15 min early and rested for 10 min prior to
their scheduled blood draw. In using this particular
protocol, we intended to balance the need to minimize
exercise for the sake of the experiment with the need to
accommodate the free-living subjects who volunteered
for our study. A total of 27 subjects chose to leave be-
tween blood draws, and it is possible that their activ-
ities while away from the WHNRC could have
influenced our results. Future studies should follow a
more stringent protocol that does not allow subjects to
leave between blood draws.
Despite the aforementioned limitations, our observa-
tions may be useful for identifying foods and ingredients
which maximize the suppression of bone resorption for
therapeutic purposes, and for generating hypotheses to
test in future studies. Identifying foods and ingredients
(e.g. MFGM), as well as meal patterns (e.g. six small
meals vs. three larger meals), which can suppress
bone resorption for a longer period in the postpran-
dial state, may lead to osteoporosis prevention strat-
egies in the long term. Additionally, it is possible that
MFGM may have interacted with other ingredients or
nutrients in the meal to give the observed response.
The possible interactive effects of MFGM with other
food ingredients, as well as the effects of MFGM on
longer-term bone outcomes such as BMD, will require
further investigation.
Conclusions
In this exploratory study, we have shown that bone re-
sorption (as measured by the biomarker CTX) is signifi-
cantly suppressed in the postprandial state, particularly
after consumption of high SFA meals that contain
MFGM. However, MFGM was not found to be a direct
moderator of the CTX response. To further elucidate
the potential role of inflammation in postprandial bone
turnover, future studies based on our observations
should 1) match test meals for individual fatty acids and
micronutrients as well as macronutrients, 2) include
measurements of postprandial bile acids, incretin hor-
mones and insulin, and 3) assess interactions of MFGM
with other food ingredients.
Additional files
Additional file 1: Nutrient composition of test meals. (DOCX 21 kb)
Additional file 2: Test meal ingredient list. (DOCX 14 kb)
Additional file 3: Correlations of CTX and selected metabolic variables
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